Microbix Biosystems, Inc. (MBXBF)
0.159
+0.01
(+3.45%)
USD |
OTCM |
Dec 19, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 22.10M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -39.31% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.667 |
| Price to Book Value | 1.106 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2438 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 77.24% |
Profile
| Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. It operates through the Antigens, QAPs and DxTM, and Other segments. The Antigens, QAPs and DxTM segment includes the development, manufacturing and sales of products relating to the medical diagnostics industry. The Other segment deals with the development and commercialization of novel and proprietary products or technologies such as Kinlytic. The company was founded by William J. Gastle in 1988 and is headquartered in Mississauga, Canada. |
| URL | http://www.microbix.com |
| Investor Relations URL | N/A |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. It operates through the Antigens, QAPs and DxTM, and Other segments. The Antigens, QAPs and DxTM segment includes the development, manufacturing and sales of products relating to the medical diagnostics industry. The Other segment deals with the development and commercialization of novel and proprietary products or technologies such as Kinlytic. The company was founded by William J. Gastle in 1988 and is headquartered in Mississauga, Canada. |
| URL | http://www.microbix.com |
| Investor Relations URL | N/A |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |